These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15501984)

  • 1. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2004 Oct; 10(20):7043-52. PubMed ID: 15501984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
    Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
    Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
    Balaian L; Ball ED
    Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD68 protein as a potential target for leukaemia-reactive CTL.
    Sadovnikova E; Parovichnikova EN; Savchenko VG; Zabotina T; Stauss HJ
    Leukemia; 2002 Oct; 16(10):2019-26. PubMed ID: 12357353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
    Balaian L; Ball ED
    Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
    Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
    Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
    Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
    Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.
    Biedermann B; Gil D; Bowen DT; Crocker PR
    Leuk Res; 2007 Feb; 31(2):211-20. PubMed ID: 16828866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
    Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
    J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
    He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
    Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.